UNITED GUARDIAN INC UG

Healthcare SIC 2844 - Perfumes, Cosmetics & Other Toilet Preparations NAICS Manufacturing › Chemical Manufacturing › Soap, Cleaning Compound, and Toilet Preparation Manufacturing derived Nasdaq

United-Guardian, Inc. ("Company") is a Delaware corporation that, through its Guardian Laboratories division, manufactures, markets and develops specialty cosmetic, personal care and sexual wellness ingredients and a line of healthcare products including pharmaceuticals and medical lubricants. We conduct various research and development ("R&D") activities. Our R&D department primarily develops new and unique specialty cosmetic and sexual wellness ingredients. We develop new products using natural and environmentally friendly raw materials, which is a priority for many of our cosmetic customers. The R&D department also modifies, refines, and expands the uses for existing products, with the goal of further developing the markets that our products are used in. All the products that we market, except for Renacidin®, are produced at our facility in Hauppauge, New York. Renacidin, a urological product, is manufactured for us by an outside contract manufacturer.

Last close 6.67 2026-10-23
Market cap $30.6M 2026-06-30 share count
52-week range 5.58 - 8.45

Valuation FY2025 figures against the last close

P/S2.9x
P/E—
P/FCF16.1x
EV/EBITDA13.0x
Dividend yield9.0%
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $10.5M$12.2M$10.9M$12.7M$13.9M$11.0M$13.6K$13.4M$13.0M$10.8M
Cost of revenue $5.4M$5.7M$5.5M$6.0M$5.7M$4.9M$5.7M$5.3M$5.3M$4.9M
Gross profit $5.1M$6.5M$5.4M$6.7M$8.2M$6.1M-$5.6M$8.1M$7.7M$5.9M
R&D $463.6K$456.8K$464.0K$490.8K$478.6K$451.2K$397.4K$399.5K$646.1K$651.8K
Total operating expenses $8.3M$8.5M$8.0M$8.7M$8.3M$7.3M$8.2M$7.9M$1.8M$1.9M
Operating income $2.2M$3.6M$2.9M$4.0M$5.7M$3.6M$5.4M$5.6M$5.2M$3.4M
Pre-tax income $2.6M$4.1M$3.3M$3.2M$5.9M$4.2M$6.0M$5.5M$5.6M$3.7M
Income tax $537.3K$857.6K$669.4K$658.2K$1.2M$856.0K$1.3M$1.1M$1.7M$1.1M
Net income $2.1M$3.3M$2.6M$2.6M$4.7M$3.3M$4.8M$4.4M$3.8M$2.6M
EPS, basic 0.460.710.560.561.01—————
EPS, diluted ————1.010.721.040.950.840.56
Shares, diluted (wtd. avg.) 4.6M4.6M4.6M4.6M4.6M—————

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $1.3M$1.9M$8.2M$830.5K$531.2K$591.4K$1.0M$550.1K$724.7K$424.3K
Short-term investments $7.3M$7.5M$851.3K$5.7M$7.6M$7.6M$6.9M$7.6M$7.7M—
Receivables $1.6M$1.4M$1.6M$1.4M$1.8M$1.4M$2.1M$1.7M$1.9M$1.6M
Inventory $1.5M$1.5M$1.2M$1.7M$1.4M$1.4M$1.2M$1.5M$1.3M$1.3M
Total current assets $12.2M$12.7M$12.3M$10.0M$11.6M$11.2M$11.6M$11.7M$11.9M$13.7M
Property, plant and equipment $907.2K$956.4K$619.2K$559.2K$658.9K$673.7K$780.7K$827.9K$942.9K$1.1M
Total assets $13.1M$13.8M$12.9M$10.6M$12.2M$11.9M$12.4M$12.5M$12.9M$14.9M
Accounts payable $480.8K$425.0K$134.4K$30.4K$410.9K$31.8K$71.4K$186.8K$354.3K$82.8K
Total current liabilities $1.7M$1.9M$1.5M$1.4M$2.3M$1.4M$1.3M$1.4M$1.4M$1.0M
Total liabilities $1.9M$1.9M$1.5M———————
Retained earnings $10.8M$11.4M$10.9M$8.8M$9.4M$9.9M$10.2M$10.5M$10.5M$13.2M
Total equity $11.2M$11.9M$11.4M$9.3M$9.8M$10.4M$10.6M$10.9M$11.4M$13.8M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $2.0M$3.5M$3.1M$2.5M$5.3M$3.6M$4.5M$5.0M$4.0M$2.3M
Depreciation and amortisation $108.2K$95.9K$105.7K$135.4K$146.0K$165.3K$175.8K$191.9K$200.7K$187.0K
Capital expenditure $59.0K$433.1K$165.7K$75.2K$116.4K$43.4K$113.8K$75.0K$38.1K$166.7K
Investing cash flow $175.3K-$7.1M$4.7M$897.6K-$183.5K-$468.7K$1.1M-$308.8K$2.8M$490.2K
Financing cash flow -$2.8M-$2.8M-$459.4K-$3.1M-$5.2M-$3.6M-$5.0M-$4.8M-$6.5M-$3.4M
Dividends paid $2.8M$2.8M$459.4K$3.1M$5.2M$3.6M$5.0M$4.8M$6.5M$3.4M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001171843-26-002251.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -10M -5M 0 5M 10M 15M Revenue, FY2016: 10.8M Gross profit, FY2016: 5.9M Net income, FY2016: 2.6M Revenue, FY2017: 13M Gross profit, FY2017: 7.7M Net income, FY2017: 3.8M Revenue, FY2018: 13.4M Gross profit, FY2018: 8.1M Net income, FY2018: 4.4M Revenue, FY2019: 13.6K Gross profit, FY2019: -5.6M Net income, FY2019: 4.8M Revenue, FY2020: 11M Gross profit, FY2020: 6.1M Net income, FY2020: 3.3M Revenue, FY2021: 13.9M Gross profit, FY2021: 8.2M Net income, FY2021: 4.7M Revenue, FY2022: 12.7M Gross profit, FY2022: 6.7M Net income, FY2022: 2.6M Revenue, FY2023: 10.9M Gross profit, FY2023: 5.4M Net income, FY2023: 2.6M Revenue, FY2024: 12.2M Gross profit, FY2024: 6.5M Net income, FY2024: 3.3M Revenue, FY2025: 10.5M Gross profit, FY2025: 5.1M Net income, FY2025: 2.1M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $10.8M $13.0M $13.4M $13.6K $11.0M $13.9M $12.7M $10.9M $12.2M $10.5M
Gross profit $5.9M $7.7M $8.1M -$5.6M $6.1M $8.2M $6.7M $5.4M $6.5M $5.1M
Net income $2.6M $3.8M $4.4M $4.8M $3.3M $4.7M $2.6M $2.6M $3.3M $2.1M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Code of ethics change The code of ethics changed, or somebody was excused from part of it. Item 5.05

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2844

TickerCompanyMarket capP/ERevenue growth
CL COLGATE PALMOLIVE CO $74.97B 35.8x 1.4%
EL ESTEE LAUDER COMPANIES INC $39.37B 217.3x 5.0%
KVUE Kenvue Inc. $37.59B 25.8x -2.1%
ELF e.l.f. Beauty, Inc. $6.74B 259.6x 24.6%
IPAR INTERPARFUMS INC $3.69B 22.0x 2.5%
COTY COTY INC. $2.84B — -1.5%
EPC EDGEWELL PERSONAL CARE Co $1.29B 52.9x -1.3%
WALD Waldencast plc $100.3M — -0.7%